Skip to main content
SpringerLink
Log in

Promotional Review: Principles and Practice

  • Current Opinion
  • Published:
Pharmaceutical Medicine Aims and scope Submit manuscript

Abstract

Reviewing promotional materials for pharmaceutical products is important to help ensure their high quality and allow recipients to be well-informed about benefits and risks. This article provides an overview of control mechanisms that can influence the overall quality of the product combined with practical advice, based on personal US and international experience. US case reports are used to illustrate examples of promotional violations, and the consequences of government enforcement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hurley D. Natural causes: death, lies and politics in America’s vitamin and herbal supplement industry. 1st ed. New York: Broadway Books; 2007. pp. 23–26, 33–35.

  2. Francer J, Izquierdo JZ, Music T, Narsai K, Nikidis C, Simmonds H, et al. Ethical pharmaceutical promotion and communications worldwide: codes and regulations. Philos Ethics Humanit Med. 2014;29(9):7.

    Article  Google Scholar 

  3. U.S. Department of Justice. Novartis to pay $422.5 million for off-label drug marketing [media release]. 2010 Sep 30. http://www.fda.gov/ICECI/CriminalInvestigations/ucm228104.htm. Accessed 31 May 2016.

  4. US Department of Justice. Pfizer to pay $2.3 billion for fraudulent marketing [media release]. 2009 Sep 2. http://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history. Accessed 31 May 2016.

  5. US Department of Justice. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data [media release]. 2012 Jul 2. https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report. Accessed 31 May 2016.

  6. Othman N, Vitry A, Roughead EE. Quality of pharmaceutical advertisements in medical journals: a systematic review. PLoS One. 2009;4(7):e6350.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Toscano A. Regulation of prescription drug promotion [Office of Prescription Drug Promotion presentation]. 2013 Jun. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM361326.pdf. Accessed 31 May 2016.

  8. BMI System. French certification of promotional materials. 2012 May 12. http://www.bmi-system.com/french-certification-promotional-materials/. Accessed 31 May 2016.

  9. Medicines and Healthcare products Regulatory Agency. Advertise your medicines. 2014 Dec 18. https://www.gov.uk/guidance/advertise-your-medicines. Accessed 31 May 2016.

  10. The Financial Brand. HSBC ‘different points of value’. 2009 Jul 6. http://thefinancialbrand.com/6361/hsbc-brand/. Accessed 31 May 2016.

  11. Food and Drug Administration. FDA Draft Guidance for Industry: presenting risk information in prescription drug and medical device promotion. 2009 May. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm155480.pdf. Accessed 31 May 2016.

  12. Abrams T. Warning letter to Shire Development Inc. 2008 Sep 25. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/ucm053995.pdf. Accessed 31 May 2016.

  13. Szydlo RT, Hubbard L. 2012. Warning letter to Forest Laboratories, Inc. 2012 Aug 1. http://www.fda.gov/downloads/Drugs/UCM314572.pdf. Accessed 31 May 2016.

  14. Abrams TW. 2012. Warning letter to Teva Pharmaceuticals USA. 2012 Mar 14. Available from URL: http://www.fda.gov/downloads/Drugs/UCM296204.pdf. Accessed 31 May 2016.

  15. Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, et al. Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States. J Gen Intern Med. 2013;28(10):1368–75 (Epub 2013 Apr 5).

    Article  PubMed  PubMed Central  Google Scholar 

  16. World Health Organization. Medical device—full definition. http://www.who.int/medical_devices/full_deffinition/en/. Accessed 31 May 2016.

  17. British Standards Institution. What is CE marking? http://www.bsigroup.com/en-GB/our-services/product-certification/ce-mark/ce-mark-frequently-asked-questions/#ce-marking. Accessed 31 May 2016.

Download references

Author information

Authors and Affiliations

  1. Merck & Co., Inc., 600 Corporate Drive, Lebanon, NJ, USA

    Christopher Allen

Authors
  1. Christopher Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Allen.

Ethics declarations

Funding

None received.

Conflict of interest

Dr Allen is an employee of Merck & Co., Inc., holding stock and restricted stock units.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Allen, C. Promotional Review: Principles and Practice. Pharm Med 30, 187–191 (2016). https://doi.org/10.1007/s40290-016-0153-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40290-016-0153-7

Keywords

Search

Navigation